help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on September 1, 2005
Endocrinology, doi:10.1210/en.2005-0607
A more recent version of this article appeared on December 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
146/12/5188    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WANG, Z.
Right arrow Articles by SWANSON, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WANG, Z.
Right arrow Articles by SWANSON, S. M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Prostate Cancer
Hazardous Substances DB
*TESTOSTERONE

Submitted on May 18, 2005
Accepted on August 22, 2005

Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3(1)/Tag Mouse

ZHUOHUA WANG, GAIL S. PRINS, KAREN T. COSCHIGANO, JOHN J. KOPCHICK, JEFFREY E. GREEN, VERA H. RAY, SAMAD HEDAYAT, KONSTANTIN T. CHRISTOV, TERRY G. UNTERMAN, and STEVEN M. SWANSON*

Departments of Medicinal Chemistry and Pharmacognosy (Z.W., S.M.S.), Surgical Oncology (S.M.S., KTC) Math, Statistics, and Computer Science (S.H.) and Medicine (T.G.U.), University of Illinois at Chicago, Chicago, IL, 60612; Department of Veterans Affairs Jesse Brown Medical Center (T.G.U.), Chicago, IL, 60612; Edison Biotechnology Institute and Department of Biomedical Sciences, Ohio University, Athens, OH (K.T.C., J.J.K.); Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, Bethesda, MD (J.E.G.); Provident Hospital of Cook County, Chicago, IL (V.H.R.)

* To whom correspondence should be addressed. E-mail: swanson{at}uic.edu.

Recent epidemiological studies suggest that elevated serum titers of insulin-like growth factor I (IGF-I), which are, to a large degree, regulated by growth hormone (GH), are associated with an increase in prostate cancer risk. The purpose of the current study was to develop the first animal models to directly test the hypothesis that a normal, functional GH/IGF-I axis is required for prostate cancer progression. The GH receptor (GHR) gene-disrupted mouse (Ghr-/-), which has less than 10% of the plasma IGF-I found in GHR wild-type mice, was crossed with the C3(1)/Tag mouse, which develops prostatic intraepithelial neoplasia (PIN) driven by the large T antigen (Tag) that progress to invasive prostate carcinoma in a manner similar to the process observed in humans. Progeny of this cross were genotyped and Tag/Ghr+/+ and Tag/Ghr-/- mice were killed at 9 months of age. Seven of 8 Tag/Ghr+/+ mice harbored PIN lesions of various grades. In contrast, only one of the 8 Tag/Ghr-/- mice exhibited atypia (P < 0.01, Fischer's exact test). Disruption of the GHR gene altered neither prostate androgen receptor expression nor serum testosterone titers. Expression of the Tag oncogene was similar in the prostates of the two mouse strains. Immunohistochemistry revealed a significant decrease in prostate epithelial cell proliferation and an increase in basal apoptotic indices. These results indicate that disruption of GH signaling significantly inhibits prostate carcinogenesis.
Key words: Mouse model of prostate cancer • growth hormone/IGF-I axis • Tag




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
S.-H. Tan and M. T Nevalainen
Signal transducer and activator of transcription 5A/B in prostate and breast cancers
Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Anzo, L. J. Cobb, D. L. Hwang, H. Mehta, J. W. Said, S. Yakar, D. LeRoith, and P. Cohen
Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression
Cancer Res., May 1, 2008; 68(9): 3342 - 3349.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Z. Wang, R. M. Luque, R. D. Kineman, V. H. Ray, K. T. Christov, D. D. Lantvit, T. Shirai, S. Hedayat, T. G. Unterman, M. C. Bosland, et al.
Disruption of Growth Hormone Signaling Retards Prostate Carcinogenesis in the Probasin/TAg Rat
Endocrinology, March 1, 2008; 149(3): 1366 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Shen, D. D. Lantvit, Q. Lin, Y. Li, K. Christov, Z. Wang, T. G. Unterman, R. G. Mehta, and S. M. Swanson
Advanced Rat Mammary Cancers Are Growth Hormone Dependent
Endocrinology, October 1, 2007; 148(10): 4536 - 4544.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. D. McKay, R. Kaaks, M. Johansson, C. Biessy, F. Wiklund, K. Balter, H.-O. Adami, C. Boillot, L. Gioia-Patricola, F. Canzian, et al.
Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 169 - 173.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. V. Silha, P. C. Sheppard, S. Mishra, Y. Gui, J. Schwartz, J. G. Dodd, and L. J. Murphy
Insulin-Like Growth Factor (IGF) Binding Protein-3 Attenuates Prostate Tumor Growth by IGF-Dependent and IGF-Independent Mechanisms
Endocrinology, May 1, 2006; 147(5): 2112 - 2121.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society